Glaucoma – Global Drug Forecast and Market Analysis to 2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Glaucoma market size across the 7MM was valued at $2.8 billion in 2020 and is expected to achieve a CAGR of more than 1% during 2020-2030. Glaucoma is one of the leading causes of blindness worldwide, especially among elderly people. The main risk factors associated with glaucoma are age, race, and family history. People with chronic illnesses are also at a higher risk for glaucoma.
The glaucoma market research report provides an overview of the risk factors, comorbidities, and global and historical trends for glaucoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of POAG and PACG, segmented by sex and age (40–49 years, 50–59 years, 60–69 years, 70–79 years, and age 80 years and older) in these markets.
Glaucoma Market Outlook
To gain more information about the glaucoma market forecast, download a free report sample
Glaucoma Market Drivers
Some of the major drivers of growth in the glaucoma market across the 7MM over the forecast period include the launch of sustained-release (SR) implants, which are expected to help meet the unmet needs in the glaucoma market by improving patient compliance. Moreover, the projected launch of products with novel mechanisms of action (MOA) to current treatment options will help in lowering patients’ intraocular pressure (IOP).
Glaucoma Market Segmentation by Class of Drugs
The key classes of drugs in the US glaucoma market are Prostaglandin Analogues, Fixed-Dose Combination Therapies, Beta Blockers, Carbonic Anhydrase Inhibitors, Alpha-Adrenergic Agonist, Cholinergic Agonist, Rho-Kinase Inhibitors, Sustained-Release Implants, Small-Interfering RNA, and LRRK2 Inhibitor. In 2020, the leading drug class in the US glaucoma market was Prostaglandin Analogues.
Glaucoma Market Analysis, by Class of Drugs in the US
For more glaucoma classes of drugs insights, download a free report sample
Glaucoma Market - Competitive Landscape
Some of the leading players in the glaucoma market are Bausch & Lamb, Nic0x, Mallinckrodt Plc, Santen, Merck, Bruschettini Srl, Aerie Pharmaceuticals, Otsuka Pharmaceutical, Aton, Thea Pharma, and Sandoz International.
Glaucoma Market Report Overview
Market Size (2020) | $2.8 billion |
CAGR (2020 – 2030) | >1% |
Key Class of Drugs | Prostaglandin Analogues, Fixed-Dose Combination Therapies, Beta Blockers, Carbonic Anhydrase Inhibitors, Alpha-Adrenergic Agonist, Cholinergic Agonist, Rho-Kinase Inhibitors, Sustained-Release Implants, Small-Interfering RNA, and LRRK2 Inhibitor |
Leading Players | Bausch & Lamb, Nic0x, Mallinckrodt Plc, Santen, Merck, Bruschettini Srl, Aerie Pharmaceuticals, Otsuka Pharmaceutical, Aton, Thea Pharma, and Sandoz International |
Scope
This report provides:
- Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline glaucoma therapeutics market revenue from 2020–2030. The annual cost of therapy and major pipeline product sales in this forecast period are included.
- Key topics covered include current glaucoma therapies, unmet needs and opportunities, and the drivers and barriers affecting treatment sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global glaucoma therapeutics market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global glaucoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the glaucoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Bausch & Lamb
Nic0x
Mallinckrodt Plc
Santen
Merck
Bruschettini Srl
Aerie Pharmaceuticals
Otsuka Pharmaceutical
Aton
Thea Pharma
Novatis
Kowa Co Ltd
Sandoz International
OmniVision
Eisai Co Ltd
Concordia International
Teofarma Srl
Sanwa Kagaku Kenkyusho
Ocular Therapeutix Inc
ViSci Ltd
Ono Pharmaceutical
D. Western Therapeutics
Sylentis SAU
pH Pharma Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What was the glaucoma market size in 2020?
The glaucoma market size was valued at $2.8 billion in 2020.
-
What is the glaucoma market growth rate?
The glaucoma market is expected to achieve a CAGR of more than 1% during 2020-2030.
-
What are the key classes of drugs in the US glaucoma market?
The key classes of drugs in the US glaucoma market are Prostaglandin Analogues, Fixed-Dose Combination Therapies, Beta Blockers, Carbonic Anhydrase Inhibitors, Alpha-Adrenergic Agonist, Cholinergic Agonist, Rho-Kinase Inhibitors, Sustained-Release Implants, Small-Interfering RNA, and LRRK2 Inhibitor.
-
Who are the leading players in the glaucoma market?
Some of the leading players in the glaucoma market are Bausch & Lamb, Nic0x, Mallinckrodt Plc, Santen, Merck, Bruschettini Srl, Aerie Pharmaceuticals, Otsuka Pharmaceutical, Aton, Thea Pharma, and Sandoz International.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.